Covestor Ltd Cuts Stock Position in Henry Schein, Inc. (NASDAQ:HSIC)

Covestor Ltd trimmed its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 16.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,661 shares of the company’s stock after selling 326 shares during the period. Covestor Ltd’s holdings in Henry Schein were worth $115,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in HSIC. Scotia Capital Inc. acquired a new position in shares of Henry Schein during the fourth quarter worth $737,000. Raymond James Financial Inc. purchased a new stake in Henry Schein during the 4th quarter worth $34,720,000. Bank of Nova Scotia lifted its holdings in Henry Schein by 0.5% in the 4th quarter. Bank of Nova Scotia now owns 286,710 shares of the company’s stock worth $19,840,000 after buying an additional 1,407 shares in the last quarter. Invesco Ltd. boosted its position in Henry Schein by 0.4% in the 4th quarter. Invesco Ltd. now owns 4,963,409 shares of the company’s stock valued at $343,468,000 after buying an additional 17,552 shares during the last quarter. Finally, FMR LLC grew its stake in shares of Henry Schein by 6.6% during the fourth quarter. FMR LLC now owns 3,498,033 shares of the company’s stock valued at $242,064,000 after acquiring an additional 217,143 shares in the last quarter. 96.62% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Henry Schein

In related news, Director Philip A. Laskawy sold 2,604 shares of the stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $71.04, for a total value of $184,988.16. Following the completion of the transaction, the director now owns 24,805 shares in the company, valued at $1,762,147.20. This represents a 9.50 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Bradford C. Connett sold 4,036 shares of the business’s stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $71.15, for a total transaction of $287,161.40. Following the sale, the chief executive officer now owns 62,688 shares in the company, valued at $4,460,251.20. This trade represents a 6.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.14% of the stock is currently owned by company insiders.

Henry Schein Stock Up 1.4 %

Shares of Henry Schein stock opened at $64.46 on Friday. Henry Schein, Inc. has a twelve month low of $60.56 and a twelve month high of $82.49. The stock has a market capitalization of $8.00 billion, a price-to-earnings ratio of 26.53, a PEG ratio of 2.13 and a beta of 0.84. The company has a current ratio of 1.42, a quick ratio of 0.82 and a debt-to-equity ratio of 0.46. The business’s 50 day simple moving average is $71.90 and its 200-day simple moving average is $72.23.

Henry Schein (NASDAQ:HSIC) last posted its earnings results on Tuesday, February 25th. The company reported $1.19 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.23 by ($0.04). The company had revenue of $3.19 billion during the quarter, compared to the consensus estimate of $3.25 billion. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. The business’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.66 earnings per share. Equities research analysts forecast that Henry Schein, Inc. will post 4.74 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on HSIC. Barrington Research reissued an “outperform” rating and issued a $90.00 price target on shares of Henry Schein in a report on Wednesday, February 26th. Bank of America upgraded Henry Schein from an “underperform” rating to a “buy” rating and increased their target price for the company from $69.00 to $84.00 in a research note on Monday, January 6th. Wells Fargo & Company started coverage on shares of Henry Schein in a research note on Friday, February 14th. They issued an “equal weight” rating and a $80.00 price target for the company. UBS Group reduced their price objective on shares of Henry Schein from $83.00 to $80.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 26th. Finally, Jefferies Financial Group boosted their target price on shares of Henry Schein from $77.00 to $80.00 and gave the stock a “hold” rating in a research report on Thursday, January 23rd. Five investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Henry Schein currently has a consensus rating of “Moderate Buy” and an average price target of $81.10.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.